Table 4.
ORs (99.9% CIs) for breast cancer cross-classified by estrogen receptor (ER)- and progesterone receptor (PR)-status (both classified as positive (+) or negative (−)) associated with selected autoimmune diseases
| ER+/PR+ breast cancer N=121,349 |
ER+/PR− breast cancer N = 25,256 |
ER−/PR+ breast cancer N = 1,946 |
ER−/PR− breast cancer N = 25,837 |
|||||
|---|---|---|---|---|---|---|---|---|
| # exposed cases |
ORa (99.9% CI) | # exposed cases |
ORa (99.9% CI) | # exposed cases |
ORa (99.9% CI) | # exposed cases |
ORa (99.9% CI) | |
| Systemic autoimmune rheumatic diseases (SARDs) | ||||||||
| Total SARDS | 6090 | 0.83 (0.72–0.87) | 1356 | 0.89 (0.81–0.99) | 124 | 1.17 (0.86–1.61) | 1405 | 0.91 (0.83–1.01) |
| Rheumatoid arthritis | 3582 | 0.79 (0.74–0.85) | 811 | 0.87 (0.76–0.98) | 72 | 1.02 (0.68–1.53) | 895 | 0.92 (0.82–1.04) |
| Systemic lupus erythematosus | 437 | 0.77 (0.63–0.93) | 109 | 0.94 (0.67–1.33) | 15 | 1.62 (0.66–3.95) | 113 | 0.91 (0.65–1.27) |
| Organ-specific autoimmune diseases | ||||||||
| Total | 6270 | 0.96 (0.91–1.02) | 1345 | 1.02 (0.92–1.12) | 103 | 1.15 (0.81–1.61) | 1311 | 0.99 (0.90–1.10) |
| Pernicious anemia | 2012 | 0.86 (0.78–0.94) | 463 | 0.95 (0.80–1.12) | 45 | 1.36 (0.82–2.26) | 447 | 0.94 (0.79–1.11) |
| Psoriasis | 1789 | 1.19 (1.07–1.32) | 352 | 1.14 (0.95–1.39) | 20 | 0.93 (0.44–1.97) | 317 | 1.04 (0.85–1.27) |
a
Variables included in the models: age, race/ethnicity, region, year of diagnosis/selection, months between entry and diagnosis/selection, mammogram, diabetes, dyslipidemia, autoimmune conditions included in the table (for analysis of total SARDs and total organ-specific autoimmune diseases, only these conditions were included in the mode l; for analyses of the individual conditions, the total variables were not included in the models, only the individual conditions). Statistically significant ORs are bolded.